THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Rajagopal Ramesh to Drug Delivery Systems

This is a "connection" page, showing publications Rajagopal Ramesh has written about Drug Delivery Systems.
Connection Strength

7.364
  1. Drug delivery approaches for HuR-targeted therapy for lung cancer. Adv Drug Deliv Rev. 2022 01; 180:114068.
    View in: PubMed
    Score: 0.665
  2. Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs. Cancer Lett. 2020 08 28; 486:18-28.
    View in: PubMed
    Score: 0.599
  3. Combinatorial Nanoparticle Delivery of siRNA and Antineoplastics for Lung Cancer Treatment. Methods Mol Biol. 2019; 1974:265-290.
    View in: PubMed
    Score: 0.545
  4. Exosomes as Theranostics for Lung Cancer. Adv Cancer Res. 2018; 139:1-33.
    View in: PubMed
    Score: 0.508
  5. Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery. Adv Cancer Res. 2018; 137:115-170.
    View in: PubMed
    Score: 0.506
  6. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine. 2018 02; 14(2):373-384.
    View in: PubMed
    Score: 0.504
  7. Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy. Sci Rep. 2017 11 07; 7(1):14674.
    View in: PubMed
    Score: 0.503
  8. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486.
    View in: PubMed
    Score: 0.488
  9. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems. Drug Dev Ind Pharm. 2017 Sep; 43(9):1391-1401.
    View in: PubMed
    Score: 0.487
  10. Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. J Biomed Nanotechnol. 2016 Jun; 12(6):1159-73.
    View in: PubMed
    Score: 0.455
  11. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomedicine. 2015; 10:6773-88.
    View in: PubMed
    Score: 0.437
  12. Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. Curr Gene Ther. 2015; 15(2):182-92.
    View in: PubMed
    Score: 0.413
  13. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm. 2014 Aug 04; 11(8):2720-33.
    View in: PubMed
    Score: 0.398
  14. Tumor-targeted exosomes for delivery of anticancer drugs. Cancer Lett. 2023 04 01; 558:216093.
    View in: PubMed
    Score: 0.181
  15. Tumor-Targeted Dendrimer Nanoparticles for Combinatorial Delivery of siRNA and Chemotherapy for Cancer Treatment. Methods Mol Biol. 2020; 2059:167-189.
    View in: PubMed
    Score: 0.146
  16. Multifaceted Applications of Chitosan in Cancer Drug Delivery and Therapy. Mar Drugs. 2017 Mar 27; 15(4).
    View in: PubMed
    Score: 0.120
  17. Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep. 2016 12 12; 6:38541.
    View in: PubMed
    Score: 0.118
  18. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 2016 Jun 21; 14(1):47.
    View in: PubMed
    Score: 0.114
  19. Nanoparticle-based cisplatin therapy for cancer. Ther Deliv. 2015 Feb; 6(2):115-9.
    View in: PubMed
    Score: 0.104
  20. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009 Dec 01; 15(23):7299-308.
    View in: PubMed
    Score: 0.072
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES